Ingestible sensor trial to track PrEP use in young men
Part of Immune system & allergy, Infections clinical trials.
This study tests an ingestible (swallowed) sensor system that can measure how consistently PrEP is taken. It may help people and clinics understand adherence (taking PrEP as prescribed) and improve PrEP support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re a young man age 18–24 and biologically male
- You are eligible for PrEP and interested in using PrEP
- You plan to take PrEP every day for 6 months
- You must be able to get PrEP as a patient at the CORE Center PrEP Clinic
- You meet one STI/risk need (HIV-positive partner, recent bacterial STI, many partners, inconsistent/no condom use, or sex for money/goods)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to help young gay and bisexual men who take PrEP medication prevent HIV but sometimes miss doses or have condomless sex. It aims to see if behavioral strategies can improve adherence to PrEP and reduce risky behaviors.
This study tests a new approach to help men at risk for HIV stay healthy by providing access to PrEP through a mobile app. The goal is to see if the program helps men start and stay on PrEP compared to standard care.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This trial tests ways to improve how well people take PrEP (a medicine that helps prevent HIV) consistently. It may help you if you’re at higher risk and are not currently on PrEP, especially around starting and staying on it.
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.